Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AnorMED Inc has initiated enrollment in a phase Ib/IIa trial to evaluate the potential of AMD070, an oral HIV entry inhibitor, in HIV-infected patients.
Subscribe to our email newsletter
The company’s clinical program for AMD070 is being conducted by leading investigators at the US Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute of Allergy and Infectious Diseases at the National Institute of Health.
The trial will be conducted at multiple centers in the US and will enroll up to 48 patients. It will evaluate the ability of AMD070 to reduce the CXCR4 viral load in HIV patients and will provide additional safety and pharmacokinetic data on the drug candidate
AMD070 is a member of a new class of HIV drugs called entry inhibitors, which prevent the virus from infecting healthy cells by blocking the CXCR4 receptor.
“This clinical study in HIV patients will determine if AMD070 has the potential to become a new and important anti-HIV drug,” said Dr Gary Calandra, vice president clinical development at AnorMED.
“We are very pleased to have initiated patient enrollment and to have the support of the ACTG and the leading clinical investigators involved in this important clinical study,” he continued.
AnorMED hopes to present data from this trial in 2005.